157 related articles for article (PubMed ID: 37565289)
1. Genetic and epigenetic prognosticators of neuroendocrine tumours of the GI tract, liver, biliary tract and pancreas: A systematic review and meta-analysis.
Mestre-Alagarda C; Srirajaskanthan R; Zen Y; Giwa M; Howard M; Ooft ML
Histopathology; 2024 Jan; 84(2):255-265. PubMed ID: 37565289
[TBL] [Abstract][Full Text] [Related]
2. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
4. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
5. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
6. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
7. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
8. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
9. NETs: organ-related epigenetic derangements and potential clinical applications.
Cives M; Simone V; Rizzo FM; Silvestris F
Oncotarget; 2016 Aug; 7(35):57414-57429. PubMed ID: 27418145
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumours: cracking the epigenetic code.
Karpathakis A; Dibra H; Thirlwell C
Endocr Relat Cancer; 2013 Jun; 20(3):R65-82. PubMed ID: 23429748
[TBL] [Abstract][Full Text] [Related]
11. Genetics and epigenetics in small intestinal neuroendocrine tumours.
Stålberg P; Westin G; Thirlwell C
J Intern Med; 2016 Dec; 280(6):584-594. PubMed ID: 27306880
[TBL] [Abstract][Full Text] [Related]
12. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
Pipinikas CP; Berner AM; Sposito T; Thirlwell C
Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
[TBL] [Abstract][Full Text] [Related]
13. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
14. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL
Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.
Mafficini A; Scarpa A
J Endocrinol; 2018 Mar; 236(3):R161-R167. PubMed ID: 29321190
[TBL] [Abstract][Full Text] [Related]
16. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
17. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
18. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
19. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]